Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP-P8
- Development stage
- Unknown
- Lead developer
- Cell Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PP-P8 is a first-in-class recombinant probiotic-based protein therapeutic developed by Cell Biotech for the treatment of metastatic colorectal cancer. The drug delivery system (DDS) utilizes a genetically engineered strain of *Pediococcus pentosaceus* (CBT-SL4) as a vehicle to deliver and secrete P8, an 8 kDa anticancer protein originally derived from *Lactobacillus rhamnosus* CBT-LR5. Upon oral administration, the probiotic vehicle reaches the intestine and releases the P8 protein, which targets Glycogen Synthase Kinase 3 Beta (GSK3β). P8 exerts its therapeutic effect through a dual mechanism: it binds to GSK3β introns to disrupt transcription and interacts with the GSK3β protein to prevent its phosphorylation-mediated inactivation. This stabilization of active GSK3β promotes the degradation of β-catenin, leading to cell cycle arrest and inhibition of tumor growth. PP-P8 is currently in Phase 1 clinical development for metastatic colorectal cancer, with planned expansions into gastric cancer and diabetes.
- Other names
- P8 (anticancer protein from Lactobacillus rhamnosus CBT-LR5)PP-P8 (recombinant probiotic-delivered P8)
02
Targets
KPNA4 (Karyopherin subunit alpha 3)GSK3 (Glycogen synthase kinase 3 beta)E3 ligase (E3 ubiquitin ligases)
Beyond the preview
Go deeper on PP-P8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PP-P8.